Advanced in Febrile Neutropenia

Dr. Leonard M. Klein

Hematology Oncology | Hematology | Oncology
8915 W Golf Rd, 
Niles, IL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Advanced in Febrile Neutropenia
8915 W Golf Rd, 
Niles, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leonard Klein is a Hematologist Oncology specialist and a Hematologist in Niles, Illinois. Dr. Klein is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Klein is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Febrile Neutropenia.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

8915 W Golf Rd, Niles, IL 60714

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Enrollment Status: Recruiting
Publish Date: September 25, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 2
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
Enrollment Status: Active_not_recruiting
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Study Phase: Phase 3
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Enrollment Status: Terminated
Publish Date: July 31, 2025
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine, Decitabine, INQOVI
Study Phase: Phase 2
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Drug, Combination product
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 15 Less Clinical Trials

9 Total Publications

Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
Journal: EJHaem
Published: November 05, 2021
Similar Doctors
Shira N. Dinner
Distinguished in Febrile Neutropenia
Dr. Shira N. Dinner
Hematology | Oncology
Distinguished in Febrile Neutropenia
Dr. Shira N. Dinner
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (16.3 miles away)
866-587-4322
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shira Dinner is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Dinner has been practicing medicine for over 19 years and is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Febrile Neutropenia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Distinguished in Febrile Neutropenia
Dr. Patrick A. Hagen
Hematology Oncology | Hematology | Oncology
Distinguished in Febrile Neutropenia
Dr. Patrick A. Hagen
Hematology Oncology | Hematology | Oncology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (13.4 miles away)
708-216-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Patrick Hagen is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Hagen is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hagen is currently accepting new patients.

Advanced in Febrile Neutropenia
Dr. Steven A. Sandler
Oncology | Hematology
Advanced in Febrile Neutropenia
Dr. Steven A. Sandler
Oncology | Hematology

Cook County

1901 W Harrison St, 
Chicago, IL 
 (15.4 miles away)
312-633-7292
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Sandler is an Oncologist and a Hematologist in Chicago, Illinois. Dr. Sandler is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Thrombocytopenia, Colorectal Cancer, Familial Colorectal Cancer, Chronic Familial Neutropenia, and Bone Marrow Aspiration. Dr. Sandler is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Klein's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 76 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile